Diagam

Executive Summary

Diagam is a Belgian diagnostics company founded in 2018, specializing in the development and production of specific protein reagents for clinical biochemistry. The company's products are designed to be compatible with all major open biochemistry analyzers, serving critical clinical fields such as cardiology, gastroenterology, and immunology. Operating as an OEM and virtual manufacturer, Diagam provides bulk reagents and dedicated, barcoded kits to laboratory partners. The company is well-positioned to capitalize on the growing demand for cost-effective, high-quality diagnostic reagents, particularly in Europe. With a focus on compatibility and ease of integration, Diagam's offerings reduce the need for laboratories to invest in proprietary systems, enabling broader access to advanced diagnostic capabilities. Although the company is relatively young and private, its niche focus and established presence in Belgium suggest steady growth potential. However, limited public information and lack of disclosed funding or revenue figures introduce uncertainty. Overall, Diagam represents a small but specialized player in the in-vitro diagnostics space, with room to expand through product line extensions and strategic partnerships.

Upcoming Catalysts (preview)

• Q4 2026Expansion of Product Portfolio with New Reagent Kits70% success
• Q2 2027Strategic Partnership with European Diagnostics Distributor60% success
• TBDCE Marking for Novel Cardiac or Gastrointestinal Biomarker Test50% success